Amer Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, New Haven, CT, outlines results from the Phase III MEDALIST study (NCT02631070), investigating the clinical benefit of luspatercept in patients with lower-risk myelodysplastic syndrome and high transfusion burden. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).